Results from a 9-year Intensive Safety Surveillance Scheme (IS3) in miglustat (Zavesca®)-treated patients

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 3, 2015, Pages 329-333

  Brand, Monika ^a   Muller, Audrey ^a   Alsop, Jonathan ^b   van Schaik, Ivo N ^c   Bembi, Bruno ^d   Hughes, Derralynn ^e  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Numerus Statistics Ltd   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Gaucher disease; Lysosomal storage disease; Miglustat; Pharmacoepidemiology; Safety; Surveillance

Indexed keywords

MIGLUSTAT; 1 DEOXYNOJIRIMYCIN; ENZYME INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; BONE PAIN; CARBOHYDRATE INTOLERANCE; CHRONIC DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE REGISTRY; DRUG APPROVAL; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; GAUCHER DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NIEMANN PICK DISEASE; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREMOR; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FOLLOW UP; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY; TRENDS;

1-DEOXYNOJIRIMYCIN; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GAUCHER DISEASE; HUMANS; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84925303425     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3760     Document Type: Article

References (15)

1. Actelion. Miglustat prescribing information. 2014; http://www.zavesca.com/pdf/ZAVESCA-Full-Prescribing-Information.pdf, 2009. Accessed 26 January, 2015.
2. Actelion. Miglustat (Zavesca) summary of product characteristics. 2014; http://www.eudrapharm.eu/eudrapharm/productDetailsAction.do. Accessed 6 May, 2014.
3. Patterson MC, Mengel E, Wijburg FA, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis 2013; 8: 12. doi:10.1186/1750-1172-8-12.
4. Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999; 281(3): 249-254.
5. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355(9214): 1481-1485. doi:10.1016/S0140-6736(00)02161-9.
6. Elstein D, Hollak C, Aerts JM, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004; 27(6): 757-766. doi:10.1023/B:BOLI.0000045756.54006.17.
7. Elstein D, Dweck A, Attias D, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 2007; 110(7): 2296-2301. doi:10.1182/blood-2007-02-075960.
8. Heitner R, Elstein D, Aerts J, et al. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 2002; 28(2): 127-133. S1079979602904973 [pii].
9. Hollak CE, Hughes D, van Schaik IN, et al. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf 2009; 18(9): 770-777. doi:10.1002/pds.1779.
10. Kuter DJ, Mehta A, Hollak CE, et al. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis 2013; 51(2): 116-124. doi:10.1016/j.bcmd.2013.04.005.
11. Biegstraaten M, Mengel E, Marodi L, et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain 2010; 133(10): 2909-2919. doi:10.1093/brain/awq198.
12. Anheim M, Lagha-Boukbiza O, Fleury-Lesaunier MC, et al. Heterogeneity and frequency of movement disorders in juvenile and adult-onset Niemann-Pick C disease. J Neurol Jan 2014; 261(1): 174-179. doi:10.1007/s00415-013-7159-9.
13. Floyd AG, Yu QP, Piboolnurak P, et al. Kinematic analysis of motor dysfunction in Niemann-Pick type C. Clin Neurophysiol 2007; 118(5): 1010-1018. doi:10.1016/j.clinph.2007.01.011.
14. Biegstraaten M, van Schaik IN, Aerts JM, et al. 'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis 2008; 31(3): 337-349. doi:10.1007/s10545-008-0832-y.
15. Belmatoug N, Burlina A, Giraldo P, et al. Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis 2011; 34(5): 991-1001. doi:10.1007/s10545-011-9368-7.